Artrya (AYA) Q2 2026 TU earnings summary

Executive summary

• Converted all three U.S. foundation partners to full commercial customers with multi-year contracts for the Salix Coronary Anatomy and Plaque modules, establishing a strong base for expansion.

• Achieved first fee-per-scan revenues in the U.S. from the Salix Coronary Plaque module, with positive clinician feedback on efficiency and workflow improvements.

• Built and deployed a U.S.-based customer success team to support integration, training, and onboarding of new clients.

• SAPPHIRE study secured six major U.S. healthcare systems as participants, establishing a strong foundation for future clinical validation and commercial expansion.

• Additional U.S. patent granted, strengthening the intellectual property portfolio.

Financial highlights

• Completed an AUD 18 million capital raise, resulting in a pro forma cash position of AUD 76.5 million at 31 December, with an additional AUD 5.6 million R&D rebate expected in the March quarter.

• Customer receipts for the quarter were $60,000, marking the start of scalable revenue, with initial fee-per-scan revenue invoiced and to be received next quarter.

• Operating outflows were $5.4 million, down from $6.1 million in the prior quarter due to one-off costs previously incurred.

• Interest income for the quarter was $0.4 million.

• Net cash outflows for the quarter were $16.3 million, reflecting treasury management and capital raising activities.

Outlook and guidance

• Targeting FDA 510(k) clearance for the Salix Coronary Flow module by 30 June 2026, with commercial launch planned for the second half of 2026.

• SAPPHIRE study to commence statistical work in the second half of the year, with preliminary results expected by year-end and full launch in early 2026.

• Full integration and ramp-up of U.S. foundation customers expected in FY 2027, with SAPPHIRE partners targeted for commercial conversion in FY 2028.

• Building a network of key opinion leaders and planning further industry presentations to drive awareness and adoption.